Innovative solution optimizes laboratory workflow and clinical information management. A world leader in in vitro diagnostics, bioMérieux presented Myla™, a revolutionary new middleware solution to improve connectivity, laboratory workflow and information management, at the 110th General Meeting of the American Society for Microbiology (ASM) in San Diego. Part of bioMérieux’s FMLA™* solutions and services, Myla is an intelligent browser-based application that consolidates and manages microbiology data generated from a variety of sources and converts these data into actionable information for treatment decisions. Designed to transform the way that laboratory managers and technicians work, Myla recaptures time spent on information retrieval and reporting activities through a simple dashboard-based user interface that provides full control of lab workflow.

bioMérieux and GlaxoSmithKline (GSK) have signed an agreement to develop a novel molecular test for cancer. In this new collaboration, the two companies will develop a theranostic test to aid oncologists in choosing the appropriate treatment for metastatic melanoma (skin cancer).

bioMérieux announces today that it has agreed on the terms for the acquisition of certain assets from AnagnosTec, a company based in the greater Berlin area, specialized in microbial identification with MALDI-TOF* mass spectrometry technology.